We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel AI-Driven Cardiac Blood Test Provides Highly Accurate Prediction of One-Year Risk for Heart Attack, Stroke, or Cardiac Death

By LabMedica International staff writers
Posted on 08 Aug 2021
Print article
Illustration
Illustration
A novel, artificial intelligence (AI)-driven blood test for cardiac risk can provide highly accurate prediction of one-year risk for heart attack, stroke, or cardiac death.

Prevencio, Inc. (Kirkland, Wash., USA) has been issued a patent by the US Patent Office for its highly accurate blood test, HART CVE, for a patient’s one-year risk of heart attack, stroke, or cardiovascular death. The company leveraged its AI-driven HART platform and expertise in cardiac blood tests to develop HART CVE. The company recently announced an international 1,500+ patient study using HART CVE. When the HART CVE test score was divided into low-risk and high-risk categories, the test predicted with 98% accuracy (negative predictive value) that a low-risk patient would not have a heart attack or major cardiac event within one year.

In addition to the HART CVE test for one-year risk of a cardiac event, Prevencio has recently launched a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries. HART CADhs was shown to be more accurate (86% AUC accuracy) than standard-of-care stress tests (52% AUC accuracy). HART CVE and HART CADhs tests are currently available to medical professionals for patient use.

“This AI-powered risk score test provides improved accuracy as compared to clinical risk factors and single protein tests. The test could be particularly useful for patients with suspected or known stable and acute heart disease, for which there are very few prognostic risk models,” said James L. Januzzi, MD, a practicing cardiologist at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School and Principal Investigator in development, validation, and ongoing testing of the HART CVE test. “In addition to leading to more appropriate care of patients, it is well-suited for a role in ‘enriching’ pharmaceutical cardiac clinical trials, which could lead to lower trial costs and reduced time to complete clinical trials.”

Related Links:

Prevencio, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.